Tag: Study

A new multicenter Phase II clinical trial, led by researchers from several institutions including Jiangsu Cancer Hospital, is showing promising results in treating patients with advanced metastatic solid tumors. This innovative treatment regimen combines hypofractionated radiotherapy (HFRT) with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor (GM-CSF), and thymosin-α1. The combination aims to enhance the immune…

If you are someone who follows developments in cancer treatment, especially in the realm of immunotherapy and radiotherapy, you may find the study titled “PD-1 Inhibitor Combined with Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study“ an intriguing read. The research explores a promising treatment combination for patients…